Michael Blumenthal with Hyro

Michael Blumenthal from Hyro joins the ViVE show floor to discuss the emerging role of AI in healthcare. She highlights how Hyro is not just talking about AI’s potential but is actively deploying it with healthcare organizations, delivering impactful results. Michael emphasizes Hyro’s success in integrating deeply into the healthcare community, focusing solely on healthcare’s unique needs and complexities. She attributes Hyro’s success to building strong relationships with CIOs and healthcare professionals, listening to their challenges, and collaboratively finding solutions. Michael also underscores the importance of long-term partnerships, ensuring that their technology continues to add value throughout the implementation process. She credits Hyro’s approach and relationships as the key to their success, wrapping up with a nod to their vibrant, community-focused company culture.

Recent Episodes

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…